Vanlev in refractory patients
This article was originally published in Pharmaceutical Approvals Monthly
Bristol-Myers Squibb could seek approval of Vanlev (omapatrilat) through a study demonstrating a benefit in patients who have persistent serious hypertension after treatment with drugs from three different antihypertensive classes, FDA's Cardiovascular & Renal Drugs Advisory Committee suggests at its July 19 meeting. The committee voted five to one against approval because of concerns that benefits shown over enalapril (a 3.2 mm Hg greater reduction in systolic blood pressure and a 1.9 mm Hg greater reduction in diastolic BP in the OCTAVE trial) do not outweigh the risk of angioedema (2.17% for omapatrilat vs. 0.68% for enalapril
You may also be interested in...
Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions
Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.
I.V. Korsuva now has an August FDA action date, which partner Vifor would commercialize in the ESRD dialysis setting while Cara works toward a broad anti-pruritus label for its oral tablet formulation.
China, Iran and especially Russia have launched campaigns aimed at undermining confidence in Western vaccines, especially Pfizer’s, according to two reports.